Search

Your search keyword '"Cesaro S"' showing total 1,018 results
Start Over Author "Cesaro S"
1,018 results on '"Cesaro S"'

1. Biosimilars in the management of neutropenia: focus on filgrastim

Author

Caselli D, Cesaro S, and Aricò M

Subjects
neutropenia, filgrastim, biosimilars, Medicine (General), R5-920
Abstract

Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time and degree of neutropenia. A biosimilar is a copy of an approved original biologic medicine whose data protection has expired. The patent for filgrastim expired in Europe in 2006 and in the US in 2013. This review analyses the available evidence to be considered in order to design a strategy of use of G-CSF and its biosimilars. The clinical and safety outcomes of biosimilars are well within the range of historically reported data for originator filgrastim. This underscores the clinical effectiveness and safety of biosimilar filgrastim in daily clinical practice. Biosimilars can play an important role by offering the opportunity to reduce costs, thus contributing to the financial sustainability of treatment programs. Keywords: neutropenia, filgrastim, biosimilars, G-CSF, fever, prophylaxis

Published
2016

3. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)

Author

Guarina, A., Farruggia, P., Mariani, E., Saracco, P., Barone, A., Onofrillo, D., Cesaro, S., Angarano, R., Barberi, W., Bonanomi, S., Corti, P., Crescenzi, B., Dell'Orso, G., De Matteo, A., Giagnuolo, G., Iori, A.P., Ladogana, S., Lucarelli, A., Lupia, M., Martire, B., Mastrodicasa, E., Massaccesi, E., Arcuri, L., Giarratana, M.C., Menna, G., Miano, M., Notarangelo, L.D., Palazzi, G., Palmisani, E., Pestarino, S., Pierri, F., Pillon, M., Ramenghi, U., Russo, G., Saettini, F., Timeus, F., Verzegnassi, F., Zecca, M., Fioredda, F., and Dufour, C.

Published
2024
Full Text
View/download PDF

4. Acute chest syndrome in children with sickle cell disease: Data from a national AIEOP cohort identify priority areas of intervention in a hub‐and‐spoke system.

Author

Munaretto, V., Corti, P., Bertoni, E., Tripodi, S. I., Guerzoni, M. E., Cesaro, S., Arcioni, F., Piccolo, C., Mina, T., Zecca, M., Cuzzubbo, D., Casale, M., Palazzi, G., Notarangelo, L. D., Masera, N., Samperi, P., Perrotta, S., Russo, G., Sainati, L., and Colombatti, R.

Subjects
SICKLE cell anemia, SYNDROMES in children, OXYGEN therapy, PAIN management
Abstract

Summary: Acute chest syndrome (ACS) is a frequent cause of hospitalization in sickle cell disease (SCD). Despite advances in acute care, many settings still lack knowledge about ACS best practices. After the AIEOP Guidelines were published in 2012, suggesting standardized management in Italy, a retrospective study was performed to assess the diagnostic and therapeutic pathways of ACS in children. From 2013 to 2018, 208 ACS episodes were presented by 122/583 kids in 11 centres. 73 were male, mean age 10.9 years, 85% African, 92% HbSS or Sβ°. In our hub‐and‐spoke system, a good adherence to Guidelines was documented, but discrepancies between reference centres and general hospitals were noted. Improvement is needed for timely transfer to reference centres, use of incentive spirometry, oxygen therapy and pain management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Acute chest syndrome in children with sickle cell disease: Data from a national AIEOP cohort identify priority areas of intervention in a hub‐and‐spoke system

Author

Munaretto, V., primary, Corti, P., additional, Bertoni, E., additional, Tripodi, S. I., additional, Guerzoni, M. E., additional, Cesaro, S., additional, Arcioni, F., additional, Piccolo, C., additional, Mina, T., additional, Zecca, M., additional, Cuzzubbo, D., additional, Casale, M., additional, Palazzi, G., additional, Notarangelo, L. D., additional, Masera, N., additional, Samperi, P., additional, Perrotta, S., additional, Russo, G., additional, Sainati, L., additional, and Colombatti, R., additional

Published
2023
Full Text
View/download PDF

7. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

Author

Di Cataldo, A., Agodi, A., Balaguer, J., Garaventa, A., Barchitta, M., Segura, V., Bianchi, M., Castel, V., Castellano, A., Cesaro, S., Couselo, J. M., Cruz, O., D’Angelo, P., De Bernardi, B., Donat, J., de Andoin, N. G., Hernandez, M. I., La Spina, M., Lillo, M., Lopez-Almaraz, R., Luksch, R., Mastrangelo, S., Mateos, E., Molina, J., Moscheo, C., Mura, R., Porta, F., Russo, G., Tondo, A., Torrent, M., Vetrella, S., Villegas, J. A., Viscardi, E., Zanazzo, G. A., and Cañete, A.

Published
2017
Full Text
View/download PDF

10. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients (vol 41, pg 1633, 2021)

Author

Hashem, H., Bucciol, G., Ozen, S., Unal, S., Bozkaya, I.O., Akarsu, N., Taskinen, M., Koskenvuo, M., Saarela, J., Dimitrova, D., Hickstein, D.D., Hsu, A.P., Holland, S.M., Krance, R., Sasa, G., Kumar, A.R., Muller, I., Sousa, M.A. de, Delafontaine, S., Moens, L., Babor, F., Barzaghi, F., Cicalese, M.P., Bredius, R., Montfrans, J. van, Baretta, V., Cesaro, S., Stepensky, P., Benedicte, N., Moshous, D., Guenno, G. le, Boutboul, D., Dalal, J., Brooks, J.P., Dokmeci, E., Dara, J., Lucas, C.L., Hambleton, S., Wilson, K., Jolles, S., Koc, Y., Gungor, T., Schnider, C., Candotti, F., Steinmann, S., Schulz, A., Chambers, C., Hershfield, M., Ombrello, A., Kanakry, J.A., and Meyts, I.

Published
2022

15. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors

Author

Styczynski, J., Tridello, G., Koster, L., Iacobelli, S., Biezen, A. van, Werf, S. van der, Mikulska, M., Gil, L., Cordonnier, C., Ljungman, P., Averbuch, D., Cesaro, S., Camara, R. de la, Baldomero, H., Bader, P., Basak, G., Bonini, C., Duarte, R., Dufour, C., Kuball, J., Lankester, A., Montoto, S., Nagler, A., Snowden, J.A., Kroger, N., Mohty, M., Gratwohl, A., Infect Dis Working Party EBMT, UAM. Departamento de Medicina, Styczynski, J., Tridello, G., Koster, L., Iacobelli, S., van Biezen, A., van der Werf, S., Mikulska, M., Gil, L., Cordonnier, C., Ljungman, P., Averbuch, D., Cesaro, S., de la Camara, R., Baldomero, H., Bader, P., Basak, G., Bonini, C., Duarte, R., Dufour, C., Kuball, J., Lankester, A., Montoto, S., Nagler, A., Snowden, J. A., Kroger, N., Mohty, M., and Gratwohl, A.

Subjects
medicine.medical_specialty, Medicina, Epidemiology, medicine.medical_treatment, Hematopoietic stem cell transplantation, Disease, Infections, survival, Communicable Diseases, Article, Cohort Studies, cause of death, Internal medicine, stem cell transplant, medicine, Humans, Haematopoietic stem cell transplantation (HSCT), Risk factor, Cause of death, Transplantation, Leukemia, stem cell transplant, cause of death, survival, business.industry, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Hematology, Settore MED/15, Death, Settore MED/01, surgical procedures, operative, Risk factors, Mycoses, Cohort, business, Cohort study
Abstract

Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980–2001) to cohort 2 (2002–2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of “unknown origin”., The study was funded by the European Group for Blood and Marrow Transplantation EBMT

Published
2019

20. New data from the italian national register of congenital coagulopathies, 2016 annual survey

Author

Abbonizio F., Hassan H. J., Riccioni R., Santagostino E., Arcieri R., Giampaolo A., Contino L., Accorsi A., Caremani A., Ettorre P. C., Giordano P., Lassandro G., Valdre L., Notarangelo L., Aru A. B., Radossi P., Tagariello G., Cultrera D., Iannaccaro P., Santoro R., Biasoli C., Di Gregorio P., Daniele F., Testa S., Serino M. L., Castaman G., Linari S. S., Morfini M., Molinari A. C., Delios G., Cantori I., Franchini M., Caimi M. T., Mancuso M. E., Peyvandi F., Marietta M., Todisco A., Speciale V., Cerbone A. M., Di Minno G., Schiavulli M., Rocino A., Spiezia M. M., Zanon E., Gagliano F., Mansueto M. F., Siragusa S., Coppola A., Quintavalle G., Rivolta G. F., Tagliaferri A., Ambaglio C., Gamba G., Marchesini E., Oliovecchio E., Dragani A., Arbasi M. C., MacChi S., Vincenzi D., Sottilotta G., Pizzini A. M., Luciani M., De Cristofaro R., Baldacci E., Mazzucconi M. G., Santoro C., Mameli L. A., Coluccia A., Marino P., Borchiellini A., Schinco P. C., Messina M., Pollio B., Ricca I., Agostini P., Cristallo A. F., Barillari G., De Angelis V., Mosanghini M. E., Feola G., Bonetti E., Cesaro S., Gandini G., Giuffrida A., Tosetto A., Abbonizio, F., Hassan, H. J., Riccioni, R., Santagostino, E., Arcieri, R., Giampaolo, A., Contino, L., Accorsi, A., Caremani, A., Ettorre, P. C., Giordano, P., Lassandro, G., Valdre, L., Notarangelo, L., Aru, A. B., Radossi, P., Tagariello, G., Cultrera, D., Iannaccaro, P., Santoro, R., Biasoli, C., Di Gregorio, P., Daniele, F., Testa, S., Serino, M. L., Castaman, G., Linari, S. S., Morfini, M., Molinari, A. C., Delios, G., Cantori, I., Franchini, M., Caimi, M. T., Mancuso, M. E., Peyvandi, F., Marietta, M., Todisco, A., Speciale, V., Cerbone, A. M., Di Minno, G., Schiavulli, M., Rocino, A., Spiezia, M. M., Zanon, E., Gagliano, F., Mansueto, M. F., Siragusa, S., Coppola, A., Quintavalle, G., Rivolta, G. F., Tagliaferri, A., Ambaglio, C., Gamba, G., Marchesini, E., Oliovecchio, E., Dragani, A., Arbasi, M. C., Macchi, S., Vincenzi, D., Sottilotta, G., Pizzini, A. M., Luciani, M., De Cristofaro, R., Baldacci, E., Mazzucconi, M. G., Santoro, C., Mameli, L. A., Coluccia, A., Marino, P., Borchiellini, A., Schinco, P. C., Messina, M., Pollio, B., Ricca, I., Agostini, P., Cristallo, A. F., Barillari, G., De Angelis, V., Mosanghini, M. E., Feola, G., Bonetti, E., Cesaro, S., Gandini, G., Giuffrida, A., and Tosetto, A.

Subjects
Blood coagulation disorder, Haemophilia B, Haemophilia A, Von Willebrand's disease, Register
Abstract

Background - In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand's disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. Materials and methods - Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-related complications. Results - In 2016, the total number of patients with congenital coagulopathies in the NRCC was 10,360: 39.8% of these patients had HA, 31.5% had vWD, 8.5% had HB, and 20.2% had less common factor deficiencies. The overall prevalence of HA and HB was 13.9/100,000 males and 3.0/100,000 males, respectively. The overall prevalence of vWD was 5.4/100,000 inhabitants. During 2016, 126 patients had current alloantibodies to factor VIII (FVIII) or factor IX (FIX) and were under treatment with bypassing agents and/or immune tolerance induction. Overall, 388 patients with a history of alloantibodies were recorded in the NRCC of whom 337 with severe HA and 12 with severe HB. Coagulation factor use, evaluated from treatment plans, was approximately 451,000,000 IU of FVIII for HA patients (7.5 IU/inhabitant), and approximately 53,000,000 IU of FIX for HB patients (0.9 IU/inhabitant). Discussion - The prevalences of HA and HB fall within the ranges reported in more developed countries; the consumption of FVIII and FIX was in line with that of other European countries (France, United Kingdom) and Canada. The NRCC, with its bleeding disorder dataset, is a helpful tool for shaping public health policies, as well as planning clinical and epidemiological research projects.

Published
2020

24. Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: an AIEOP retrospective analyses

Author

Perruccio, K., Menconi, M., Galaverna, F., Pagliara, D., Carraro, F., Fagioli, F., Calore, E., Biffi, A., Baretta, V., Massei, M. S., Capolsini, I., Faraci, M., Verna, M., Soncini, E., Caniglia, M., Locatelli, Franco, and Cesaro, S.

Subjects
Oncology, medicine.medical_specialty, allogeneic stem cell transpantaiton, Adenoviridae Infections, MEDLINE, Organophosphonates, Brincidofovir, allogeneic stem cell transpantaiton, adenovirus infection, Antiviral Agents, ADENOVIRUS, adenovirus infection, Cytosine, Internal medicine, medicine, Humans, Adenovirus infection, Retrospective Studies, Transplantation, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, medicine.disease, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, HSCT, Stem cell, brincidofovir, business, medicine.drug
Published
2021

26. L'impiego del cinabro e del blu egizio negli intonaci dipinti della villa romana di Cottanello

Author

Sfameni C., Colosi F., Prestileo F., Nunziante Cesaro S., Paladini A., and Trojsi G.

Subjects
microscopia ottica, FT-IR, SEM-EDS, villa romana, XRF, blu egizio, cinabro
Abstract

During the archaeological research carried out by the Institute for Studies on Ancient Mediterranean, now Institute of Heritage Science (CNR) at the Roman Villa in Cottanello (Latium) since 2013, a specific interest was reserved for painted plasters, with regard to a general census of the parts still in situ and to the characterization of the constituent elements of painted surfaces. In particular, samples from different rooms as well as fragments found in the room 25 and fragments from the first excavations have been analysed using Optical Microscopy of polished sections, Scanning Optical Microscope Observation equipped with Energy Dispersion Probe, Fourier Transform Infrared Spectroscopy, X-Ray Fluorescence. They are representative of the main colours found on the plasters and most of them could be stylistically positioned between III and IV Pompeian style (main building phase of the villa - 1st century AD). The results allowed highlighting the presence of cinnabar and Egyptian blue and their ways of use.

Published
2021

28. The EBMT activity survey: 1990–2010

Author

Passweg, J R, Baldomero, H, Gratwohl, A, Bregni, M, Cesaro, S, Dreger, P, Witte, T de, Farge-Bancel, D, Gaspar, B, Marsh, J, Mohty, M, Peters, C, Tichelli, A, Velardi, A, de Elvira, C Ruiz, Falkenburg, F, Sureda, A, and Madrigal, A

Published
2012
Full Text
View/download PDF

29. Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases

Author

Candoni A, Klimko N, Busca A, Di Blasi R, Shadrivova O, Cesaro S, Zannier ME, Verga L, Forghieri F, Calore E, Nadali G, Simonetti E, Muggeo P, Quinto AM, Castagnola C, Cellini M, Del Principe MI, Fracchiolla N, Melillo L, Piedimonte M, Zama D, Farina F, Giusti D, Mosna F, Capelli D, Delia M, Picardi M, Decembrino N, Perruccio K, Vallero S, Aversa F, Fanin R, Pagano L, SEIFEM Group (Epidemiological Surveillance of Infections in Haematological Diseases), Candoni, A., Klimko, N., Busca, A., Di Blasi, R., Shadrivova, O., Cesaro, S., Zannier, M. E., Verga, L., Forghieri, F., Calore, Aldo, Nadali, G., Simonetti, E., Muggeo, P., Quinto, A. M., Castagnola, C., Cellini, M., Del Principe, M. I., Fracchiolla, N., Melillo, L., Piedimonte, M., Zama, D., Farina, F., Giusti, D., Mosna, F., Capelli, D., Delia, M., Picardi, M., Decembrino, N., Perruccio, K., Vallero, S., Aversa, F., Fanin, R., Pagano, L., Candoni A, Klimko N, Busca A, Di Blasi R, Shadrivova O, Cesaro S, Zannier ME, Verga L, Forghieri F, Calore E, Nadali G, Simonetti E, Muggeo P, Quinto AM, Castagnola C, Cellini M, Del Principe MI, Fracchiolla N, Melillo L, Piedimonte M, Zama D, Farina F, Giusti D, Mosna F, Capelli D, Delia M, Picardi M, Decembrino N, Perruccio K, Vallero S, Aversa F, Fanin R, Pagano L, and SEIFEM Group (Epidemiological Surveillance of Infections in Haematological Diseases)

Subjects
0301 basic medicine, Male, Antifungal Agents, haematological disease, Aspergillosis, fungal CNS infectious, haematological diseases, leukaemia, neurologic complications, Zygomicosis, 030207 dermatology & venereal diseases, 0302 clinical medicine, Central Nervous System Fungal Infections, Epidemiology, Paranasal Sinuses, Sinusitis, Child, Adolescent, Adult, Aged, Cerebrospinal Fluid, Child, Preschool, Epidemiologic Studies, Female, Fungi, Hematologic Neoplasms, Humans, Middle Aged, Survival Analysis, Treatment Outcome, Young Adult, Debridement, medicine.diagnostic_test, aspergillosis, fungal cns infectious, zygomicosis, neurologic complication, General Medicine, medicine.anatomical_structure, Infectious Diseases, Cohort, medicine.drug, medicine.medical_specialty, fungal CNS infectiou, Aspergillosi, 030106 microbiology, Dermatology, 03 medical and health sciences, Internal medicine, Biopsy, medicine, Preschool, Invasive fungal infection, central nervous system, onco-haematologic patients, Survival analysis, Voriconazole, business.industry, Zygomicosi, medicine.disease, Paranasal sinuses, 2708, business, Settore MED/15 - Malattie del Sangue
Abstract

Invasive fungal infections (IFI) of the Central Nervous System (IFI-CNS) and Paranasal Sinuses (IFI-PS) are rare, life-threatening infections in haematologic patients, and their management remains a challenge despite the availability of new diagnostic techniques and novel antifungal agents. In addition, analyses of large cohorts of patients focusing on these rare IFI are still lacking. Between January 2010 and December 2016, 89 consecutive cases of Proven (53) or Probable (36) IFI-CNS (71/89) and IFI-PS (18/89) were collected in 34 haematological centres. The median age was 40 years (range 5-79); acute leukaemia was the most common underlying disease (69%) and 29% of cases received a previous allogeneic stem cell transplant. Aspergillus spp. were the most common pathogens (69%), followed by mucormycetes (22%), Cryptococcus spp. (4%) and Fusarium spp. (2%). The lung was the primary focus of fungal infection (48% of cases). The nervous system biopsy was performed in 10% of IFI-CNS, and a sinus biopsy was performed in 56% of IFI-PS (P = 0.03). The Galactomannan test on cerebrospinal fluid has been performed in 42% of IFI-CNS (30/71), and it was positive in 67%. Eighty-four pts received a first-line antifungal therapy with Amphotericine B in 58% of cases, Voriconazole in 31% and both in 11%. Moreover, 58% of patients received 2 or more lines of therapy and 38% were treated with a combination of 2 or more antifungal drugs. The median duration of antifungal therapy was 60 days (range 5-835). A surgical intervention was performed in 26% of cases but only 10% of IFI-CNS underwent neurosurgical intervention. The overall response rate to antifungal therapy (complete or partial response) was 57%, and 1-year overall survival was 32% without significant differences between IFI-CNS and IFI-PS. The overall mortality was 69% but the IFI attributable mortality was 33%. Mortality of IFI-CNS/PS remains high but, compared to previous historical data, it seems to be reduced probably due to the availability of newer antifungal drugs. The results arising from this large contemporary cohort of cases may allow a more effective diagnostic and therapeutic management of these very rare IFI complications in haematologic patients.

Published
2018

30. Improvement in the outcome of invasive fusariosis in the last decade

Author

Nucci, M., Marr, K. A., Vehreschild, M. J. G. T., de Souza, C. A., Velasco, E., Cappellano, P., Carlesse, F., Queiroz-Telles, F., Sheppard, D. C., Kindo, A., Cesaro, S., Hamerschlak, N., Solza, C., Heinz, W. J., Schaller, M., Atalla, A., Arikan-Akdagli, S., Bertz, H., Castro, Galvão C., Jr, Herbrecht, R., Hoenigl, M., Härter, G., Hermansen, N. E. U., Josting, A., Pagano, L., Salles, M. J. C., Mossad, S. B., Ogunc, D., Pasqualotto, A. C., Araujo, V., Troke, P. F., Lortholary, O., Cornely, O. A., Anaissie, E., and Roilides, E.

Published
2014
Full Text
View/download PDF

36. Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

Author

Santagostino E., Riva A., Cesaro S., Esposito S., Matino D., Mazzucchelli R. I., Molinari, Angelo Claudio, Mura R., Notarangelo L. D., Tagliaferri A., Di Minno G., Clerici M., Ambaglio C., Brigida Aru A., Baldacci E., Barillari G., Basso M., Bernasconi S., Bertamino M., Bertoni E., Biasoli C., Federica Biguzzi E., Bonetti E., Borchiellini A., Bulgarelli S., Cabibbo S., Cantori I., Castaman G., Castiglia P., Coluccia A., Coppetelli U., Coppola A., Cultrera D., De Candia E., Delios G., Di Gennaro L., Di Gregorio P., Di Minno M., Dragani A., Pietro Ettorre C., Franchini M., Galli M., Gallo G., Giordano P., Giuffrida G., Iannaccaro P., Lassandro G., Lazzareschi I., Linari S., Luciani M., Macchi S., Malcangi G., Malizia R., Marietta M., Marino R., Massoud M., Gabriella Mazzucconi M., Milan M., Morfini M., Napolitano M., Pasca S., Pedrazzi P., Peyvandi F. A., Piscitelli L., Pollio B., Preti P., Quintavalle G., Radossi P., Raso S., Ricca I., Rocino A., Santoro C., Carlotta Santoro R., Sarolo L., Schiavoni M., Schiavulli M., Sciancalepore P., Luisa Serino M., Mario Siragusa S., Sottilotta G., Svahn J., Valdre L., Cristina Vedovati M., Zanon E., Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, Angelo Claudio, Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, E., Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, I., Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., and Zanon, E.

Subjects
Adult, medicine.medical_specialty, Consensus, Delphi Technique, Vaccination schedule, Delphi method, haemophilia, 030204 cardiovascular system & hematology, Hemophilia A, Haemophilia, immunization, Hemophilia B, bleeding disorder, factor VIII inhibitor, vaccination, Child, Evidence-Based Medicine, Humans, Italy, Vaccination, 03 medical and health sciences, 0302 clinical medicine, Vaccine administration, Medicine, In patient, Clinical Haemophilia, Genetics (clinical), business.industry, Original Articles, Hematology, General Medicine, Evidence-based medicine, medicine.disease, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Immunization, Family medicine, Original Article, business, 030215 immunology
Abstract

Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5‐point Likert‐type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence‐ and consensus‐based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

Published
2019

41. EVENTI ACUTI NEI PAZIENTI CON MALATTIA DREPANOCITICADURANTE LA FASE I DEL LOCKDOWN: RISULTATI DELLA SURVEY NAZIONALE NEI CENTRI AIEOP

Author

Munaretto, V, Voi, V, Palazzi, G, Notarangelo, L, Corti, P, Baretta, V, Casale, M, Barone, A, Cuzzubbo, D, Samperi, P, Tripodi, Si, Giona, F, Miano, M, Nocerino, D, Del Vecchio, G, Sau, A, Filippini, B, Casciana, Ml, Arcioni, F, Migliavacca, M, Saracco, P, Gorio, C, Cesaro, S, Perrotta, S, Zecca, M, Giordano, P, Fasoli, S, Russo, G, Sainati, L, and Colombatti, R.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results